ATN biomarker dataset now available on the EPND Hub – advancing research into Alzheimer’s disease, Parkinson’s disease, and Dementia with Lewy Bodies

2025-05-22

(Press-News.org)

The European Platform for Neurodegenerative Diseases (EPND) is proud to announce the release of the ATN dataset from its first biomarker case study, now accessible via the EPND Hub. This marks a major step forward in collaborative, cross-disease research tackling neurodegenerative conditions that affect millions across Europe. The release underlines EPND’s mission to foster data and biosample sharing to accelerate breakthroughs in neurodegenerative disease research.

A multi-cohort dataset to study shared disease mechanisms

The biomarker case study builds on the invaluable contributions of cohort investigators and research teams who provided biosamples and clinical data for the ATN biomarker case study. The ATN dataset includes harmonised clinical and biomarker data from over 350 participants across ten European research cohorts, spanning seven clinical centres in Denmark, Germany, Czechia, Norway, Switzerland, Luxembourg, and the Netherlands. Centralised biomarker analyses, conducted by EPND partners at the University of Gothenburg, used Roche’s NeuroToolKit to measure cerebrospinal fluid (CSF) and plasma Aß42, Aß40, p-tau181, neurofilament light chain (NfL), and CSF α-synuclein. Data were then harmonised by researchers at the University of Maastricht, where data analyses were also completed.

“In the ATN dataset, biomarker measurements are linked to information on demographics, clinical characteristics, lifestyle factors, imaging, and genetics,” said Pieter Jelle Visser, EPND co-Coordinator and Principal Investigator of the biomarker case study. “The dataset also includes rich clinical assessments covering cognition, motor function, mood, and more - a valuable tool to study disease mechanisms across Alzheimer’s disease, Parkinson’s disease, and dementia with Lewy bodies.”

Researchers can now request access to the full dataset through the EPND Hub, which includes an extensive range of tools to support discovery and collaborative analysis.

New insights to inform diagnosis and trial design

At the 2024 Alzheimer’s Association International Conference, EPND partner Marianna Rizzo (University of Maastricht) presented findings from this case study that challenge traditional diagnostic boundaries. The study showed that amyloid and tau pathologies - typically linked to AD - also appear in DLB and, to a lesser extent, PD. A consistent association between p-tau181 and α-synuclein across all three diseases points to potentially shared pathological processes.

These insights have significant implications for biomarker-driven diagnosis and the future design of clinical trials aimed at overlapping neurodegenerative mechanisms.

The EPND Hub: enabling cross-cohort discovery at scale

The ATN dataset joins over 100 research studies now discoverable through the EPND Hub. This growing platform brings together metadata on studies, biosample collections and datasets from across 25+ countries, covering 12 disease areas and over 265,000 participants - from AD and PD to rarer disorders like Huntington’s disease and ataxias.

"To ensure the Hub is as useful as possible, we have incorporated a vast array of metadata, such as the number of plasma and CSF samples that are available, and which clinical variables are collected,” said EPND co-Coordinator Anthony Brookes, Professor of Genetics at the University of Leicester. “This way, researchers have a single location to easily search – and discover – the complete landscape of neurodegeneration studies in Europe.”

Designed by researchers for researchers, the EPND Hub offers seamless data and biosample discovery, access brokerage, and analysis. Key features include:

Advanced discovery tools - Search, filter, and visualise datasets and biosamples, explore data dictionaries, and submit access requests. Study visibility - Support for structured, secure collaboration across studies and cohorts. Expert ELSI support - Guidance on GDPR compliance, ethics approvals, and legal frameworks such as the European Health Data Space. Federated access – Cross-catalogue syndication, with the Hub acting as a unified access point to a wide range of resources. Secure cloud analytics - Interoperability with the AD Workbench connects personal, cloud-based workspaces for advanced data analysis.

New opportunities for collaborative research

A notable feature of the EPND Hub is its interoperability with the Alzheimer's Disease Data Initiative's AD Workbench, a secure, cloud-based data platform and analytics environment that empowers researchers around the world to share, access and analyse data across platforms - facilitating global data sharing in Alzheimer's disease research. Thanks to this interoperability, registered users can use a single set of login credentials to view and request available datasets across both platforms, completing their analyses within personal workspaces on the AD Workbench. This interconnected ecosystem makes it easier than ever to share, request, and work with neurodegenerative disease data at scale.

According to Niranjan Bose, Interim Executive Director of the AD Data Initiative and co-Lead of EPND: “The integration of the EPND Hub and AD Workbench provides more opportunities for researchers to collaborate, share, access, and analyse data, advancing our shared goal of accelerating discoveries in neurodegenerative disease research.”

EPND welcomes researchers worldwide to register on the EPND Hub, explore its growing catalogue of studies, biosample collections and datasets - including the new ATN dataset - and join a global effort to advance the understanding and treatment of neurodegenerative diseases.

Acknowledgement

The EPND consortium brings together experts in neurodegeneration research, data science, diagnosis and treatment from 29 public and private organisations. The EPND project has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU) under grant agreement No. 101034344. The IMI JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

END

ELSE PRESS RELEASES FROM THIS DATE:

Frequent large-scale wildfires are turning forests from carbon sinks into super‑emitters

2025-05-22

Richmond Hill, Canada – 6 May 2025 — Forests once hailed as reliable carbon sinks are rapidly becoming “super‑emitters” as record‑breaking wildfires sweep boreal, Amazonian, and Australian landscapes. Today’s climate policies and voluntary carbon markets seldom account for the sharp rise in fire‑driven emissions. A new publication by the United Nations University Institute for Water, Environment and Health (UNU‑INWEH), Beyond Planting Trees: Taking Advantage of Satellite Observations to Improve Forest Carbon Management and Wildfire Prevention, warns about the unintended consequences of current ...

In vitro cancer model reveals how tumor cells access the bloodstream

2025-05-22

Tokyo, Japan – Tumors are made up of millions of cells, and removing all of these cells surgically or eliminating them with medication becomes much more difficult after the cancer has spread to other parts of the body. Now, in a study published this month in iScience, an interdisciplinary team comprising researchers from the Institute of Industrial Science, The University of Tokyo, Kanazawa University, Institute of Science Tokyo, and Kyorin University School of Medicine has determined exactly how these tumor cells are able to accomplish intrabody travel to form tumors elsewhere. Small clusters of circulating tumor cells, which are cells that detach from tumors ...

Fine-tuning osteoclast development: a targeted approach to bone disease

2025-05-22

Bone-destructive diseases such as osteoporosis and chronic inflammatory arthritis affect millions of people worldwide, causing pain, fractures, and decreased quality of life. These conditions often result from the dysregulation of osteoclasts—specialized cells responsible for breaking down bone tissue. Today, many promising treatments target the receptor activator of nuclear factor kappa B ligand (RANKL)-RANK-tumor necrosis factor receptor-associated factor 6 (TRAF6) signaling pathway, which controls ...

New insights into migraine-related light sensitivity

2025-05-22

Knowing the molecule behind light sensitivity in migraines could open the door to better treatments Scientists in the UK, Australia and China have identified a brain molecule called NEAT1 that appears to play a central role in triggering light sensitivity (photophobia), a common and debilitating symptom of migraines. Their findings, published in The Journal of Headache and Pain, highlight how this molecule affects the brain's pain response, contributing to the uncomfortable reaction to light that's common during migraines. NEAT1 belongs to a group of molecules known as long noncoding RNAs. Unlike most RNA, which carries instructions for making ...

Positive mindset about ageing in over-60s linked to better recovery after a fall

2025-05-22

There is a strong association between an older person’s view of how they are ageing and how well they will physically recover after a fall. That is the finding of a new research study from Imperial College London and Coventry University, which is the first to suggest how important psychological factors may be in post-fall physical recovery. The study is published in the Journal of the American Geriatrics Society. Falls in older adults are a major health concern because they can lead to high levels of physical disability and hospitalisation, as well as affecting people’s ability to live independently. The consequences of falls in older ...

The Lancet: Additional imaging techniques detect early stage cancers missed by mammograms in women with dense breasts, finds trial

2025-05-21

The Lancet: Additional imaging techniques detect early stage cancers missed by mammograms in women with dense breasts, finds trial In women with dense breasts (breasts with relatively low levels of fatty tissue) and a negative mammogram, supplemental imaging techniques detect early-stage cancers, with imaging techniques three times more effective than ultrasound, finds a phase 3 randomised control trial published in The Lancet. Women with extremely dense breasts, about 10% of those aged 50-70 years in the UK, face a fourfold increased ...

Antidepressant withdrawal symptoms more common among long-term users

2025-05-21

People who have been taking antidepressants for more than two years are substantially more likely to experience withdrawal symptoms compared to short-term users when they come off the medication, finds a new study led by UCL researchers. Long-term users also tend to experience worse withdrawal symptoms, and for a longer period of time, than short-term users, and are less likely to be able to stop taking the drug when they attempt to do so, according to the findings published in Psychiatry Research. The study’s lead author Dr Mark Horowitz, visiting clinical researcher at UCL Division of Psychiatry, said: “Our findings confirm what many researchers ...

Illinois study: Novel AI methodology improves gully erosion prediction and interpretation

2025-05-21

URBANA, Ill. – Gully erosion is the most severe form of soil erosion, and it can seriously impact agricultural fields, contributing to sediment loss and nutrient runoff into waterways. Gullies can be triggered suddenly by a single heavy rainfall event, creating deep channels that are difficult to rehabilitate even with heavy machinery. Accurately predicting where gully erosion is likely to occur allows agricultural producers and land managers to target their conservation efforts more effectively. In a new study, University of Illinois Urbana-Champaign researchers use a new AI-driven approach that combines machine learning with an interpretability ...

Urban areas have higher rates of high-dose opioid prescriptions

2025-05-21

Researchers from the University of Missouri School of Medicine have shed light on what populations are more likely to be prescribed a high dose of opioid medication. This increases their risk of developing opioid use disorder. Opioids like hydrocodone or oxycodone are typically prescribed to relieve intense pain. A prescription can become an addiction; side effects include building a tolerance to the medication – so the patient has to take a higher dose to feel relief – or becoming physically dependent on the drug. These ...

Lotions, perfumes curb potentially harmful effects of human oxidation field, study finds

2025-05-21

Irvine, Calif., May 21, 2025 — In a paper published today in Science Advances, researchers at the University of California, Irvine, Germany’s Max Planck Institute for Chemistry, Pennsylvania State University and other international institutions report that the application of personal care products such as fragrances and body lotions suppresses a potentially unhealthy “human oxidation field” that exists around our bodies. This zone, which was the subject of a paper by the same team published in Science in 2022, is created when oils and fats on skin react with ozone, an important oxidant in the indoor environment. ...

ATN biomarker dataset now available on the EPND Hub – advancing research into Alzheimer’s disease, Parkinson’s disease, and Dementia with Lewy Bodies

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: